Media Library

Chief Audit Officer since July 1, 2025

Board member since 2025

Chair since 2025

The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create sustainable value for diverse stakeholders. It follows requirements of the Swiss Code of Obligations and various voluntary reporting frameworks and standards.

The Annual Report 2024, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices.

The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create sustainable value for diverse stakeholders. It follows requirements of the Swiss Code of Obligations and various voluntary reporting frameworks and standards.

A focus on innovation and competitiveness will attract more R&D investments and support the conduct of more clinical trials in Europe.

Exterior view of our large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.

Highly trained specialists on the production line of our radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.

Examining materials inside the refrigeration room of our radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.

Using specialized equipment on the production line at our radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.

Conducting quality control at our state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.